Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 3/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | GCGR | P47871 | 6/20 | 0.36 |
| ▸ | GHSR | Q92847 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1022110 | 0.95 | PTGS1 (0.46) | PTGS1PTGS2HTTUSP2ALDH1A1 | |
| SCHEMBL1019980 | 0.89 | PTGS1 (0.48) | PTGS1PTGS2HTTUSP2ALDH1A1 | |
| SCHEMBL1021894 | 0.85 | PTGS1 (0.43) | PTGS1PTGS2GHSR | |
| SCHEMBL1023950 | 0.84 | PTPN1 (0.42) | PTGS1PTGS2HTT | |
| SCHEMBL1021324 | 0.84 | PTGS2 (0.48) | PTGS1PTGS2GCGRGHSR | |
| SCHEMBL1022353 | 0.84 | TLR8 (0.37) | PTGS2HTTALDH1A1 | |
| SCHEMBL1021652 | 0.83 | PTGS1 (0.48) | PTGS1PTGS2GCGRGHSRGRM2 | |
| SCHEMBL1022376 | 0.82 | PTGS1 (0.50) | PTGS1PTGS2HTTUSP2ALDH1A1 | |
| SCHEMBL1022344 | 0.81 | RARB (0.45) | ALDH1A1HPGDHSD17B10MAPT | |
| SCHEMBL1023688 | 0.81 | PTGS2 (0.51) | PTGS1PTGS2HTTALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1841729-B1 | 2-CYCLOPENTEN-1-ONE OXIME DERIVATIVES INHIBITING PRODUCTION OF TNF-ALPHA | AMOREPACIFIC CORP (KR) | 2011-01-12 | — | — | EP | claimed |
| US-8013187-B2 | 2-cyclopenten-1-one oxime derivatives inhibiting production of TNF-α | AMOREPACIFIC CORPORATION (KR) | 2011-09-06 | — | — | US | disclosed |
| EP-1841729-B1 | 2-CYCLOPENTEN-1-ONE OXIME DERIVATIVES INHIBITING PRODUCTION OF TNF-ALPHA | AMOREPACIFIC CORP (KR) | 2011-01-12 | — | — | EP | disclosed |
| US-20090036501-A1 | 2-Cyclopenten-1-One Oxime Derivatives Inhibiting Production of TNF-Alpha | AMOREPACIFIC CORPORATION (KR) | 2009-02-05 | — | — | US | disclosed |
| EP-1841729-A1 | 2-CYCLOPENTEN-1-ONE OXIME DERIVATIVES INHIBITING PRODUCTION OF TNF-ALPHA | Amorepacific Corporation (KR) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006059867-A1 | 2-CYCLOPENTEN-1-ONE OXIME DERIVATIVES INHIBITING PRODUCTION OF TNF-ALPHA | AMOREPACIFIC CORPORATION (KR) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036501-A1 | 2-Cyclopenten-1-One Oxime Derivatives Inhibiting Production of TNF-Alpha | TNF, PDE4A, PDE3B | PTGS1 15/4885PTGS2 27/4885HTT 4657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.